Brought to you by 
Urovant gains global rights to ICI's gene therapy for OAB
01 Jun 2022
Executive Summary
Roivant Sciences GMBH's Urovant Sciences Ltd. licensed exclusive worldwide development, manufacturing, and commercialization rights to Ion Channel Innovations LLC's naked DNA gene therapy hMaxi-K, for overactive bladder (OAB).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Site Specific
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Urovant gains global rights to ICI's gene therapy for OAB
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice